We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

EUROIMMUN AG

EUROIMMUN is an international provider of medical laboratory products for autoimmune, infection, allergy and molecula... read more Featured Products: More products

Download Mobile App




NVL Identified as ANA Target to Narrow Serological Gap in Systemic Sclerosis

By LabMedica International staff writers
Posted on 03 Jun 2025

Anti-nuclear autoantibodies (ANA) are important biomarkers of systemic autoimmune rheumatic diseases (SARD) and play a crucial role in disease identification and clinical decision-making. More...

They are detected using the indirect immunofluorescence assay (IFA) on HEp-2 cells as the gold standard, followed by monospecific confirmatory assays. However, there is a subset of SARD patients with unknown ANA reactivity. For example, about 20% of systemic sclerosis (SSc) patients with a positive nuclear pattern in IFA have autoantibodies against an unknown target antigen. In a new study published in Frontiers in Medicine, researchers have identified nuclear valosin-containing-protein-like (NVL) as the target antigen of ANA in a patient with suspected systemic autoimmune disease.

In the collaborative study undertaken by EUROIMMUN (Lübeck, Germany) and Charité - Universitätsmedizin Berlin (Berlin, Germany), researchers found that the serum of the index patient displayed a homogeneous nucleolar staining pattern on HEp-2 cells and monkey liver (EUROIMMUN IFA BIOCHIP Mosaic), but negative results with 27 ANA target antigens on confirmatory immunoblots (EUROLINE). NVL was identified as the target antigen by immunoprecipitation and mass spectrometry. Results were confirmed using competitive inhibition experiments, cell-based assay (CBA) and immunoblots based on recombinant antigen. The prevalence of anti-NVL autoantibodies was subsequently investigated in 693 patients with SARD and 150 healthy controls using line blot. Anti-NVL autoantibodies were detected in four out of 378 patients with SSc, representing 1.1% of this cohort, but not in 315 patients with other SARD or in healthy controls.

Two of the four anti-NVL-positive patients additionally exhibited other SSc-relevant autoantibodies, namely anti-centromere and anti-PM-Scl100 autoantibodies. The researchers concluded that anti-NVL autoantibodies may be a suitable marker to help narrow the serological gap in SSc. NVL belongs to ATPases associated with various cellular activities. It shows a high level of amino acid similarity to valosin-containing protein (VCP), which has also been described as a target antigen in autoimmune diseases. Further studies will help to determine if anti-NVL reactivity correlates with a specific SSc phenotype or therapy response. The NVL antigen is now included in the EUROLINE Systemic Sclerosis Profile 2 (EUROIMMUN), together with 12 established antigens associated with SSc and overlap syndromes. This assay is the only commercially available line blot containing NVL. The line blot offers the advantage of multiplex analysis of a broad spectrum of relevant autoantibodies in parallel.

Related Links:
EUROIMMUN
Charité - Universitätsmedizin Berlin


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Multilevel Whole Blood Calibrator Set
6PLUS1
New
Enterovirus Test
Quanty Enterovirus System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Custom hardware and software for the real-time detection of immune cell biophysical signatures in NICU (Photo courtesy of Pediatric Research, DOI:10.1038/s41390-025-03952-y)

First-Of-Its-Kind Device Profiles Newborns' Immune Function Using Single Blood Drop

Premature infants are highly susceptible to severe and life-threatening conditions, such as sepsis and necrotizing enterocolitis (NEC). Newborn sepsis, which is a bloodstream infection occurring in the... Read more

Pathology

view channel
Image: Mimix Reference Standards are cell-line derived to maintain genomic complexity and mimic patient material across molecular diagnostics workflows (Photo courtesy of Revvity)

New Cancer Testing Standards to Improve Diagnostic Accuracy for Oncology Labs

Accurate diagnosis, including the identification of genomic markers, is essential for determining the most effective cancer treatments for patients. To ensure this, laboratories require reliable reference... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.